Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Rhea-AI Summary

Anixa (NASDAQ: ANIX) will hold its 2026 Annual Meeting of Stockholders virtually on March 10, 2026 at 10:00 a.m. PT, open to all interested parties. Following formal business, CEO Dr. Amit Kumar will present clinical and regulatory updates across the oncology pipeline.

Key highlights include a regulatory approval for substantial dose escalation in the ongoing Phase 1 ovarian cancer CAR-T trial and final Phase 1 breast cancer vaccine data that met primary endpoints with favorable tolerability and protocol-defined immune responses in the majority of participants.

The presentation will conclude with a live question-and-answer session. Access: www.virtualshareholdermeeting.com/ANIX2026.

Positive

• Regulatory approval for substantial dose escalation in Phase 1 ovarian CAR-T
• Final Phase 1 breast cancer vaccine data met primary endpoints
• Breast vaccine showed favorable tolerability and immune responses in majority

Negative

• None.

News Market Reaction – ANIX

-0.67%

1 alert

-0.67% News Effect

On the day this news was published, ANIX declined 0.67%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Breast vaccine Phase 1 size: 35 participants Immune response rate: 74% Max CAR-T dose: 1×10⁹ cells/kg +5 more

8 metrics

Breast vaccine Phase 1 size 35 participants Completed Phase 1 breast cancer vaccine trial

Immune response rate 74% Protocol-defined immune responses in Phase 1 breast cancer vaccine

Max CAR-T dose 1×10⁹ cells/kg Upper range allowed for ovarian cancer CAR-T protocol

Longest survival 28 months Ovarian cancer CAR-T Phase 1 survival observation

Fiscal 2025 net loss $11,028,000 Fiscal year ended October 31, 2025

Accumulated deficit $251,677,000 As of October 31, 2025

Cash & investments $15,174,000 Cash, cash equivalents and short-term investments as of October 31, 2025

ATM capacity $100,000,000 At-the-market equity program for future common stock sales

Market Reality Check

Price: $2.98 Vol: Volume 87,929 is 0.59x th...

low vol

$2.98 Last Close

Volume Volume 87,929 is 0.59x the 20-day average, suggesting muted trading ahead of the update. low

Technical Shares at $2.98 are trading below the 200-day MA ($3.42) and 45.39% under the 52-week high, while still 27.84% above the 52-week low.

Peers on Argus

ANIX was down 1.97% with mixed peer moves: SRZN up 9.79% while STTK, TCRX, ADAG ...

ANIX was down 1.97% with mixed peer moves: SRZN up 9.79% while STTK, TCRX, ADAG and PYXS fell between 0.51% and 5.37%, pointing to stock-specific dynamics rather than a uniform biotech move.

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Conference keynote	Positive	+1.7%	Keynote on FSHR‑mediated CAR‑T trial at major research retreat.
Feb 9	Clinical update	Positive	+0.7%	Encouraging survival in Phase 1 ovarian CAR‑T and major dose escalation.
Feb 2	Naming milestone	Positive	-3.3%	USAN Council approval of non‑proprietary name for CAR‑T therapy.
Jan 27	IP expansion	Positive	-0.3%	Mexican patent allowance expanding IP for breast cancer vaccine.
Dec 15	IND transfer	Positive	-8.9%	Transfer of IND and plan for Phase 2 breast cancer vaccine trial.

Pattern Detected

Recent ANIX news often relates to early-stage oncology progress; market reactions have been split, with some positive clinical/regulatory milestones met by price declines.

Recent Company History

Over the last few months, ANIX has reported multiple oncology milestones. Ovarian cancer CAR‑T updates included encouraging survival data and major dose escalation approval on Feb 9, 2026, while a USAN non‑proprietary name for lira‑cel was secured on Feb 2, 2026. The breast cancer vaccine program advanced with Mexican patent allowance on Jan 27, 2026 and prior IND transfer and Phase 1 completion on Dec 15, 2025. The current annual meeting update consolidates these clinical and regulatory developments for investors.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-10

Anixa has an active Form S-3 shelf registration filed on 2025-09-10, covering multiple security types such as common stock, preferred stock, warrants and units. The shelf is noted as not yet effective and shows no recorded usage, indicating no takedowns have been executed under this registration in the provided data.

Market Pulse Summary

This announcement frames the 2026 annual meeting as a venue to summarize recent progress, including ...

Analysis

This announcement frames the 2026 annual meeting as a venue to summarize recent progress, including encouraging ovarian cancer CAR‑T survival data and final Phase 1 breast cancer vaccine results that met primary endpoints. Prior filings show ANIX is still pre‑revenue, with a fiscal 2025 loss of $11,028,000 and cash of $15,174,000, and it maintains an at-the-market equity program up to $100,000,000 plus an unused Form S-3 shelf. Investors may track upcoming Phase 2 vaccine plans, CAR‑T dose‑escalation cohorts, and additional regulatory milestones.

Key Terms

car-t, phase 1, vaccine, investigational new drug (ind), +4 more

8 terms

car-t medical

"Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation"

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

phase 1 medical

"ongoing Phase 1 ovarian cancer CAR-T trial; and Final Phase 1 data"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

vaccine medical

"Final Phase 1 data from the breast cancer vaccine program"

A vaccine is a medical product that teaches the body’s defenses to recognize and fight a specific infectious germ, like a practice drill that prepares soldiers before a battle. For investors it matters because vaccines can create large, recurring revenue streams, drive regulatory scrutiny and manufacturing scale, affect public health and demand, and expose companies to risks such as approval delays, safety issues or supply problems that influence stock value.

investigational new drug (ind) regulatory

"transfer of the Investigational New Drug (IND) application for its breast cancer vaccine"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

non-proprietary name regulatory

"approved liraltagene autoleucel as the non-proprietary name for its FSHR-targeted CAR-T therapy"

A non-proprietary name is the official, generic name assigned to a drug or medical product that is not owned by any single company, like a person’s legal name versus a brand nickname. It matters to investors because the non-proprietary name is used in approvals, prescribing, and labeling, and signals when a product can become a standard treatment or face generic competition — factors that directly affect sales, pricing and long-term market value.

at-the-market equity program financial

"current at-the-market equity program that permits up to $100 million of future"

An at-the-market equity program lets a company sell newly issued shares directly into the open market at the current trading price through a broker, rather than in a single, prearranged block. It provides flexible, on-demand access to cash—like drawing small amounts from a credit line—but increases the number of shares outstanding, which can reduce existing shareholders’ ownership percentage and put downward pressure on the stock price, so investors monitor program size and pacing.

options financial

"stock option to purchase up to 175,000 shares of common stock at an exercise price"

Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.

net tangible book value financial

"net tangible book value per share of $0.46 as of July 31, 2025"

Net tangible book value is the per-share value of a company if you take all its physical assets and cash, subtract what it owes, and ignore intangible items like patents or brand names. Think of it like the cash you’d split among owners if a business sold its furniture and buildings but not its reputation. Investors use it as a conservative benchmark to judge whether a stock is cheaply priced relative to hard, sellable assets.

AI-generated analysis. Not financial advice.

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting") on Tuesday, March 10, 2026, at 10:00 a.m. Pacific Time in a virtual format. The Meeting will be open to all interested parties, including non-stockholders.

Following the formal business and voting portion of the Meeting, Anixa Chairman and CEO Dr. Amit Kumar will deliver an investor presentation and corporate update. The presentation will include a review of recent clinical milestones across the Company's oncology pipeline, including:

• Encouraging survival observations and regulatory approval for substantial dose escalation in the Company's ongoing Phase 1 ovarian cancer CAR-T trial; and
• Final Phase 1 data from the breast cancer vaccine program, which met primary endpoints and demonstrated favorable tolerability and protocol-defined immune responses in the majority of participants.

The presentation will be followed by a live question-and-answer session.

The Meeting may be accessed online at: www.virtualshareholdermeeting.com/ANIX2026

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-host-2026-annual-meeting-of-stockholders-and-provide-corporate-update-highlighting-recent-clinical-and-regulatory-progress-302700688.html

SOURCE Anixa Biosciences, Inc.

FAQ

When is Anixa's (ANIX) 2026 Annual Meeting and how can I attend?

The Annual Meeting is on March 10, 2026 at 10:00 a.m. PT. According to the company, the meeting is virtual and open to all at www.virtualshareholdermeeting.com/ANIX2026 with a live question-and-answer session following the presentation.

What did Anixa announce about its Phase 1 ovarian cancer CAR-T trial (ANIX)?

Anixa announced regulatory approval for substantial dose escalation in its ongoing Phase 1 ovarian CAR-T trial. According to the company, this approval enables higher dosing levels to evaluate safety and potential efficacy in the trial.

What were the results of Anixa's Phase 1 breast cancer vaccine (ANIX)?

The final Phase 1 breast cancer vaccine data met primary endpoints and showed favorable tolerability. According to the company, protocol-defined immune responses occurred in the majority of participants in the study.

Who will present Anixa's corporate update at the March 10, 2026 meeting (ANIX)?

Anixa's chairman and CEO, Dr. Amit Kumar, will deliver the investor presentation and corporate update. According to the company, the talk will review recent clinical milestones and be followed by live Q&A.

Will non-stockholders be able to join Anixa's (ANIX) 2026 meeting and Q&A?

Yes, the company said the meeting will be open to all interested parties, including non-stockholders. According to the company, the virtual format allows external attendees to view the presentation and participate in the live question-and-answer session.